#Japan #Tokyo #AbbVie #Upadacitinib #Vitiligo

AbbVie's Application for Upadacitinib

AbbVie, headquartered in Minato-ku, Tokyo, has submitted an application to the Japanese authorities for the additional approval of Upadacitinib as a treatment for vitiligo. This drug is a low-molecular Janus kinase (JAK) inhibitor administered orally once a day and is already approved for eight indications in Japan, including atopic dermatitis.

Vitiligo is an acquired condition characterized by the reduction or complete loss of melanocytes, the pigment cells responsible for skin coloration. The non-segmental form of vitiligo (NSV), which constitutes approximately 84% of all vitiligo cases, manifests as symmetrical white spots on both sides of the body. It is categorized as a chronic autoimmune disease, where self-reactive immune cells destroy melanocytes. The progression of NSV can be unpredictable and may occur even after a long period of stability.

In Japan, the prevalence of vitiligo is estimated to be around 0.5% to 1%, which aligns with global statistics. About half of patients develop the condition before the age of 20, and there is no significant difference in incidence rates between genders.

Vitiligo is not merely a cosmetic issue; it has substantial physical and mental health implications for those affected. Reports indicate that up to 70% of vitiligo patients experience mental health disorders, such as depression or anxiety, linked closely to the burden of their condition. This social isolation can lead to challenges in various life circumstances, including education, employment, and social activities. For children, experiences of bullying and teasing can seriously disrupt identity formation and peer relationships.

Management of vitiligo requires tailored treatment strategies, aiming either to inhibit disease progression or promote repigmentation. However, there are currently no approved systemic therapies targeting vitiligo, making Upadacitinib's application significant as it could provide a new treatment option.

The application for additional approval is based on the outcomes of two key trials focused on NSV:

• - International Phase 2 Study (M19-051)
• - International Phase 3 Study (M19-044)

What is Upadacitinib?

Developed by AbbVie, Upadacitinib is a selective JAK inhibitor being explored for multiple immune-related conditions. It demonstrates functional selectivity, preferentially inhibiting signaling through JAK1 or JAK1/3 compared to the cytokine receptors that signal through JAK2. In Japan, Upadacitinib received its manufacturing and sales approval in January 2020 for patients with rheumatoid arthritis who had inadequate responses to existing therapies. It has since expanded its indications, gaining approvals for conditions such as:

• - Psoriatic arthritis (May 2021)
• - Atopic dermatitis (August 2021)
• - Ankylosing spondylitis (May 2022)
• - Moderate to severe ulcerative colitis (September 2022)
• - Axial spondyloarthritis (February 2023)
• - Moderate to severe Crohn's disease (June 2023)
• - Giant cell arteritis (June 2025)

About AbbVie

AbbVie's mission is to deliver innovative medicines that address serious health issues while tackling ongoing medical challenges. The company focuses on enhancing individual lives through advancements in therapeutic areas like immunology, oncology, neuroscience, and aesthetic medical treatments, notably through its Allergan Aesthetics portfolio. More information about AbbVie can be accessed at AbbVie and on their social media platforms such as LinkedIn, Facebook, Instagram, X, and YouTube. In Japan, AbbVie is committed to developing products primarily in immunology, liver disease, neuroscience, oncology, and eye care, as well as its aesthetics portfolio.

References:
1. Japanese Dermatological Association Q&A (Vitiligo)
2. Oiso et al., Dermatology Research and Practice 2011
3. Taneja et al., Indian Dermatology Online Journal 2021
4. Ezzedine et al., The Lancet 2015
5. Mazzei Weiss, Cutis 2020
6. Ezzedine et al., Pigment Cell & Melanoma Research 2012
7. Taïeb & Picardo, N Engl J Med 2009
8. Alikhan et al., J Am Acad Dermatol 2011
9. FDA Voice of the Patient 2021
10. Ezzedine et al., Am J Clin Dermatol 2021
11. Bassiouny et al., J Cosmet Dermatol 2021
12. Krüger & Schallreuter, Acta Derm Venereol 2015
13. Porter et al., Cutis 1987
14. Bibeau et al., JAMA Dermatol 2023
15. Pun et al., Dermatologic Clinics 2021
16. Silverberg & Silverberg, Pediatr Dermatol 2014
17. Parsad et al., Health Qual Life Outcomes 2003
18. Castellano-Lopezosa et al., Acta Derm Venereol 2025
19. Seneschal, Dermatol Pract Concept 2023
20. Ucuz et al., Clin Exp Dermatol 2021
21. Japanese Dermatological Association Guidelines 2025
22. RINVOQ Summary of Product Characteristics, 2021